Health Care • Biotechnology: Pharmaceutical Preparations
$1.94 ▼ -0.07
(-3.48%)
MKT CAP: $40.8M • VOL: 76.0K
52W L $2 52W H $5
ROARABLE / RQD
D- • 35/100
PIOTROSKI
2 / 9
GRCE // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2026-03-31 | FY 2024
FILED 2025-03-31 | FY 2023
FILED 2024-03-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$11.1M | -$16.7M | -$12.9M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$7.8M | -$9.6M | -$12.9M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$8.9M | -$14.9M | -$12.3M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$8.9M | -$14.9M | -$12.3M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -18.9% | -32.1% | — |
| Cash & Short-Term Equivalents | $18.7M | $11.1M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $64.9M | $52.1M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR GRCE.